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Background: Propofol is used as an induction and maintenance agent for general anesthesia but it can cause adverse 
reactions like hyperlipidemia, growth of microorganisms, and pulmonary embolisms. Microemulsion propofol 
was developed to avoid these side effects but incidence and severity of pain on injection is higher than with lipid 
emulsion propofol. We aimed to compare the effects of sufentanil in analgesic doses for reducing the injection pain 
of microemulsion propofol.
Methods: The candidates included eighty patients, 19-60 years old and ASA I­II. They were randomly classified 
into four groups and pretreated with normal saline, sufentanil 0.1 μg/kg, 0.2 μg/kg or 0.3 μg/kg before injection of 
microemulsion propofol. Five minutes after receiving pretreatment drug, 2 mg/kg of microemulsion propofol was 
injected and VAS was recorded. 
Results: There were no significant differences in the incidence of injection pain among the groups. Severity of 
injection pain was significantly lower in the sufentanil 0.3 μg/kg group than normal saline and sufentanil 0.1 μg/
kg group. Significant differences in blood pressure and heart rate were observed in sufentanil groups only after 
endotracheal intubation. One patient each in sufentanil 0.1 μg/kg and 0.3 μg/kg group experienced mild cough, one 
from sufentanil 0.3 μg/kg group experienced dizziness and another showed signs of hypoxia. One patient each in 
normal saline and sufentanil 0.1 μg/kg group showed clinical symptoms of phlebitis in the injection area. 
Conclusions: Pretreatment with sufentanil 0.3 μg/kg reduced the severity of microemulsion propofol injection pain 
without increasing arterial blood pressure and heart rate after endotracheal intubation. (Korean J Anesthesiol 2011; 
60: 83­89)
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Introduction
    Propofol is absorbed rapidly in central nerve tissue, assists 
with fast establishment of anesthesia, redistributes and 
metabolizes promptly from the central tissue to other tissues, 
and has a short half­life. For these reasons, it is used to induce 
general anesthesia, but it might cause vascular pain in case of 
injection [1]. Frequently used lipid emulsion propofol has 1% 
propofol dissolved in 10% soy bean oil, including 2.25% glycerol 
and 1.2% purified egg phosphatide (lecithin, emulsifier). 
However, this may lead to pulmonary embolism [2,3], and soy 
bean oil might facilitate microorganism proliferation [4,5]. In 
addition, adverse effects caused by the injection of lipid profiles, 
such as hypercholesterol and pancreatitis are reported [1,6].
    Microemulsion propofol is developed to remove or reduce 
adverse effects such as hypercholesterol, microorganism 
proliferation, and pulmonary embolism by eliminating lipid 
profiles, and it is pharmacodynamically and biologically equal 
to ingredients of lipid emulsion propofol. There is no difference 
in effects or safety within dose ranges (2 mg/kg) [7­9], but 
it is shown that pain is more severe in the case of injection 
compared to lipid emulsion propofol [10].
    As for lipid emulsion propofol, several methods are assessed 
in clinical trials to prevent or reduce injection pain. One method 
is the injection of small amounts of opioids before injecting 
lipid emulsion propofol [11,12]. However, a study reported that 
pain was not effectively reduced by injecting 0.01 mg (0.15 μg/
kg/min) of 2 ml sufentanil [12]. There is no study available on 
the effects of sufentanil on microemulsion propofol, which has 
more severe injection pain. 
    In this study, 0.1 μg/kg, 0.2 μg/kg, and 0.3 μg/kg of sufentanil 
were injected as a pretreatment to reduce the injection pain 
of microemulsion propofol. The effects on injection pain, 
changes in blood pressure and heart rate after endotracheal 
intubation, and abnormal responses were compared. Based on 
these results, we attempted to determine the optimal dose of 
sufentanil for the reduction of injection pain.
Materials and Methods
    This study included 80 patients who were scheduled for 
general anesthesia and aged between 19 and 60 years old. 
They were selected by random sampling and double blinding, 
which included in physical status classification I, II of American 
Society of Anesthesiologists. After obtaining approval of 
the institutional review board, sufficient explanation of the 
study purpose and methods was given to the patients and 
informed consent was obtained. Patients who had experience 
of hypersensitivity towards propofol, epileptics, patients with 
cardiovascular and respiratory system diseases, kidney, liver 
and hypovolemic patients, pregnant women, persons under 40 
kg and over 90 kg, and patients over Mallampati grade 3 were 
excluded from this study.
    Before leaving the ward, midazolam 0.04 mg/kg and 
glycopyrrolate 0.2 mg were injected as premedication. The 
patients took 20­gauge of intravenous line on the back of his 
hand, and maintained 5 ml/kg/hr of fluid speed after checking 
whether there was any inconvenience or abnormal status 
even in case of fast fluid injection prior to the clinical trials. 
Before induction, hemodynamic responses of patients were 
monitored by installing ECG, pulse oxygen saturation (SpO2), 
and noninvasive blood pressure.
    General anesthesia was carried out by microemulsion 
propofol (Aquafol
Ⓡ, Daewon Pharm., Korea), and patients were 
divided into 4 groups by a computer­generated random table, 
which included the saline pretreatment group (control group), 
sufentanil 0.1 μg/kg pretreatment group, sufentanil 0.2 μg/
kg pretreatment group, and sufentanil 0.3 μg/kg pretreatment 
group. 
    All patients were explained that injection pain might occur 
and as for pretreatment drugs, an anesthesiologist who did 
not participate in the experiment, combined the appropriate 
doses of saline 5 ml or sufentanil for each group with saline 
before induction, made the total 5 ml, and kept it at room 
temperature. The anesthesiologist who participated in the 
experiment did not know the division between groups. After 
checking whether the breath of patients were well maintained 
by monitoring sufficient oxygen supply through masks, pulse 
oxygen saturation, and respiration rate via various monitoring 
equipments, pretreatment was carried out for 10 seconds [11]. 
Considering 5 minutes, which shows the maximized effect of 
sufentanil [12], if the respiration was not maintained, patients 
were asked to take deep breath orally. In case there was no 
response, a face mask was prepared for ventilation assistance. 
    According to each group, 5 minutes after saline or sufentanil 
pretreatment, 2 mg/kg microemulsion propofol (1%) was 
injected at a speed of 1 ml/sec [11,13], and after loss of 
consciousness to enable muscle relaxation and endotracheal 
intubation, all patients were injected with succinylcholine 1 
mg/kg, ventilated with 100% oxygen using a face mask, and 
endotracheal intubation was carried out. After endotracheal 
intubation, vecuronium 0.1 mg/kg was injected, and desflurane 
or sevoflurane was applied for anesthesia maintenance, 
whereas EtCO2 was maintained as 30-35 mmHg with nitrous 
oxide 50% and oxygen as fresh gas flow 4 L/min.
    Systolic and diastolic blood pressure and heart rate were 
measured before pretreatment (baseline), 5 minutes after 
sufentanil injection, after loss of eyelid reflex, right after 
endotracheal intubation, and 5 minutes after endotracheal 
intubation. 85 www.ekja.org
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    As a measure of evaluation on pain, visual analogue scale 
score (VAS; 0 mm, no pain, 100 mm, worst pain imaginable) 
was explained to the patients before the surgery, and this study 
divided the level of pain in detail into none, mild pain over 10 
mm and less than 30 mm, moderate pain over 30 mm and less 
than 70 mm, and severe pain over 70 mm. Before eyelid reflex 
loss, if the patients claimed pain voluntarily, VAS score was 
assessed by questions, and if there was no voluntary pain claim, 
the answers were derived by questions orally at intervals of 5 
seconds and the relevant anesthesiologist evaluated the degree 
of pain [12].
    We observed whether skeletal muscle stiffness or hypoxia 
[11] occurred through the patients’ response or pulse oxygen 
saturation until microemulsion propofol injection was done. 
We recorded bradycardia (under 45 beats/min in this study), 
hypoxia (SpO2 < 90%), cough and chest wall tightness or 
dizziness by a medical examination after sufentanil injection was 
done. Erythema, muscle spasm, phlebitis due to microemulsion 
propofol injection, and abnormal responses (pain, edema, 
phlebitis) of the injection area were observed in a recovery room 
and 24 hours after the surgery. An anesthesiologist evaluated 
recall on injection pain in a recovery room without knowing the 
group classification.
    Effect size of 4­group based on the results of the pilot test was 
0.379, and the total sample size was 80 including 20 in each 
group, calculated by one­way ANOVA, two­sided test, level of 
significance 0.05, and power 0.8. 
    All results were shown as mean ± standard deviation, and 
the SPSS program (version 12.0, SPSS Inc., USA) was used for 
statistical analysis. Analysis of variance (ANOVA) was applied 
to age, weight, height, and chi­square test for gender to analyze 
demographic data. Chi­square test was applied to compare 
the effects of sufentanil pretreatment to the incidence and 
the degree of injection pain of microemulsion propofol. For 
comparison on doses, ANOVA and post hoc test (Duncan) were 
applied. For blood pressure and heart rate measurements, one 
way repeated ANOVA was applied to compare the difference 
in groups and the Tukey test was applied for post­hoc analysis 
and one way ANOVA was applied to compare the difference 
between groups and the Holm­Sidak test was applied for post­
hoc analysis. It was assumed that P value < 0.05 was statistically 
significant. 
Results
    The age, weight and height of each group did not show any 
significant difference. Overall, females (66.3%) were higher 
than their male counterparts (34%), but there was no significant 
difference by each group based on gender (P > 0.05, Table 1).
    Regarding the degree of pain, VAS was 70.5 ± 12.3 mm in 
the control group, and 48 ± 14.7 mm, 41.5 ± 24.5 mm, and 33 
± 21.3 mm in sufentanil 0.1 μg/kg, 0.2 μg/kg, and 0.3 μg/kg 
pretreatment group, respectively. VAS was significantly lower 
in sufentanil pretreatment groups than in the control group. 
The degree of pain was significantly lower in sufentanil 0.3 
μg/kg pretreatment group compared to sufentanil 0.1 μg/kg 
pretreatment group (P = 0.000, Table 2). With regards to the 
incidence of injection pain, there were 20 persons in the control 
group, 20 persons in the sufentanil 0.1 μg/kg pretreatment 
group, 19 persons in the sufentanil 0.2 μg/kg pretreatment 
group, and 18 persons in the sufentanil 0.3 μg/kg pretreatment 
group, which did not show a significant difference between 
the control and sulfentanil pretreatment groups. As for mild 
pain, 8 persons in the sufentanil 0.2 μg/kg pretreatment group 
and 11 in the sufentanil 0.3 μg/kg pretreatment group were 
significantly higher than 0 in the control group and 4 in the 
sufentanil 0.1 μg/kg pretreatment group. As for moderate pain, 
13 persons in the sufentanil 0.1 μg/kg pretreatment group was 
significantly higher than 7 persons in the sufentanil 0.2 μg/kg 
pretreatment group and 5 persons in 0.3 μg/kg pretreatment 
group. As for severe pain, sufentanil pretreatment groups were 
significantly lower than the control group (P = 0.000, Table 3). As 
for over moderate pain, all patients in control group, 16 persons 
in sufentanil 0.1 μg/kg pretreatment group, 11 persons in 
sufentanil 0.2 μg/kg pretreatment group, 7 persons in sufentanil 
0.3 μg/kg pretreatment group claimed pain, which does not 
show significant difference between the control and sufentanil 
pretreatment groups.
Table 1.  Demographic Characteristics of Patients
Groups
Normal 
saline
(n = 20)
Sufentanil
0.1 μg/kg
(n = 20)
0.2 μg/kg
(n = 20)
0.3 μg/kg
(n = 20)
Age (yr)
Weight (kg)
Height (cm)
Gender (M/F)
37.7 ± 11.1
62.0 ± 5.9
158.9 ± 7.2
3/17
42.8 ± 11.3
62.5 ± 8.8
162.1 ± 6.9
7/13
41.4 ± 11.6
67.3 ± 12.0
165.0 ± 9.5
11/9
39.3 ± 1.8
63.9 ± 9.1
161.9 ± 9.3
6/14
Values are mean ± SD or number of patients. No significant 
differences between groups.
Table 2.  Comparison of Visual Analogue Scale (VAS) Score between 
Groups
Groups
Normal 
saline
(n = 20)
Sufentanil
0.1 µg/kg
(n = 20)
0.2 µg/kg
(n = 20)
0.3 µg/kg
(n = 20)
VAS score
(mm)
70.5 ± 12.3 48.0 ± 14.7* 41.5 ± 24.5* 33.0 ± 21.3*,†
Values are mean ± SD. *P < 0.05 vs. normal saline group, 
†P < 0.05 
vs. sufentanil 0.1 µg/kg.86 www.ekja.org
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    Systolic and diastolic blood pressure significantly increased 
from the baseline in the control group right after endotracheal 
intubation and significantly decreased 5 minutes after endo­
tracheal intubation. Systolic and diastolic blood pressure 
decreased significantly in the sufentanil 0.1 μg/kg and 0.2 μg/
kg pre  treat  ment groups 5 minutes after endotracheal intu­
bation and decreased significantly in the sufentanil 0.3 μg/kg 
pretreatment groupright after endotracheal intubation and 5 
minutes after endotracheal intubation. Systolic and diastolic 
blood pressure decreased significantly in the sufentanil 0.3 
μg/kg pretreatment group right after endotracheal intubation 
compared to the control, sufentanil 0.1 μg/kg and sufentanil 0.2 
μg/kg pretreatment groups (Fig. 1 and 2). Heart rate significantly 
increased from the baseline in the control group right after 
endotracheal intubation and 5 minutes after endotracheal 
intubation, and significantly increased in sufentanil 0.1 μg/
kg and sufentanil 0.2 μg/kg pretreatment groups right after 
endotracheal intubation. Right after endotracheal intubation, 
the heart rate significantly decreased in the sufentanil 0.3 μg/
kg pretreatment group compared to the control group. Five 
minutes after endotracheal intubation, sufentanil 0.1 μg/kg, 0.2 
μg/kg, 0.3 μg/kg pretreatment groups significantly decreased 
compared to the control group (Fig. 3). 
    After pretreatment injection, 1 person complained of 
mild cough in both the sufentanil 0.1 μg/kg and 0.3 μg/kg 
Table 3.  Incidence and Intensity of Pain during Injection of Micro-
emulsion Propofol and Recalls in Post Anesthesia Care Unit (PACU)
Normal 
saline
(n = 20)
Sufentanil
0.1 µg/kg
(n = 20)
0.2 µg/kg
(n = 20)
0.3 µg/kg
(n = 20)
Pain
    None
    Mild
    Moderate
    Severe
Total incidence
Recall
0 (0)
0 (0)
4 (20)
16 (80)
20 (100)
14 (70)
0 (0)
4 (20)
13 (65)
3 (15)*
20 (100)
13 (65)
1 (5)
8 (40)*,†
7 (35)
†
4 (20)*
19 (95)
12 (63.2)
2 (10)
11 (55)*,†
5 (25)
†
2 (10)*
18 (90)
4 (22.2)*
Values are numbers of patient (%). Mild pain: visual analog scale < 
30 mm, Moderate pain: visual analog scale 30-70 mm, Severe pain: 
visual analog scale > 70 mm. *P < 0.05 vs. normal saline group, 
†P < 
0.05 vs. sufentanil 0.1 µg/kg.
Fig. 1. Change of systolic blood pressure (SBP) from pre-anesthesia 
to different times for endotracheal intubation. Values are mean ± SD. 
SBP: systolic blood pressure, 5 min: 5 minutes after pretreatment, 
LOE: loss of eyelid reflex, Intu: after tracheal intubation, Intu5: 5 
minutes after tracheal intubation. *P < 0.05 vs. normal saline group, 
†P < 0.05 vs. sufentanil 0.1 μg/kg, 
‡P < 0.05 vs. sufentanil 0.2 μg/kg, 
§P < 0.05 vs. baseline value.
Fig. 2. Change of diastolic blood pressure (DBP) from pre-anesthesia 
to different times for endotracheal intubation. Values are mean ± SD. 
DBP: diastolic blood pressure, 5 min: 5 minutes after pretreatment, 
LOE: loss of eyelid reflex, Intu: after tracheal intubation, Intu5: 5 
minutes after tracheal intubation. *P < 0.05 vs. normal saline group, 
†P < 0.05 vs. sufentanil 0.1 μg/kg, 
‡P < 0.05 vs. sufentanil 0.2 μg/kg, 
§P < 0.05 vs. baseline value.
Fig. 3. Change of heart rate (HR) from pre-anesthesia to different 
times for endotracheal intubation. Values are mean ± SD. HR: 
heart rate, 5 min: 5 minutes after pretreatment, LOE: loss of eyelid 
reflex, Intu: after tracheal intubation, Intu5: 5 minutes after tracheal 
intubation. *P < 0.05 vs. normal saline group, 
†P < 0.05 vs. baseline 
value.87 www.ekja.org
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pretreatment group. One person claimed slight dizziness in 
the sufentanil 0.3 μg/kg pretreatment group, and 1 person in 
the sufentanil 0.3 μg/kg pretreatment group had their pulse 
oxygen saturation drop temporarily to 86% after injection, but 
recovered to 100% after taking a deep breath.
    One patient each with symptoms of phlebitis on the injection 
area 24 hours after surgery was observed in the control and 
sufentanil 0.1 μg/kg pretreatment group, respectively. 
    43 patients recalled injection pain in the recovery room; 14 in 
the control group, 13 in the sufentanil 0.1 μg/kg pretreatment 
group, 12 in the sufentanil 0.2 μg/kg pretreatment group, and 
4 in the sufentanil 0.3 μg/kg pretreatment group. In addition, 
injection pain was recalled less in the sufentanil 0.3 μg/kg 
pretreatment group compared to the control group (Table 3).
Discussion
    Injecting microemulsion propofol after pretreatment of 
sufentanil did not reduce the incidence of injection pain 
significantly compared to cases where pretreatment was not 
carried out. In pretreatment with sufentanil 0.3 μg/kg, the 
degree of injection pain reduced significantly.
    As for microemulsion propofol (Aquafol
Ⓡ), oil phase is 
1% propofol itself, and aqueous phase is distilled water 
and phosphate buffer solution. As surfactants (emulsifier), 
there is 10% purified poloxamer 188 (PP188), a nonionic 
block copolymer surfactant, and for nonionic surfactant, 
macrogol­15­hydroxysterate (0.7% polyethylene glycol 660 
hydroxystearate, Solutol HS 15; BASF Company Ltd., Seoul, 
Korea) was freshly added for recomposing microemulsion 
propofol [7], and the size of droplet organizing emulsion was 0.1   
μm or less than 100 nm [4].
    Injection pain of lipid emulsion propofol occurred in 28-
90% of subjects [1]. According to the study of Sim et al. [10], 
when assessing injection pain as VAS (0-100 mm) in case of 
anesthesia induction, VAS of microemulsion propofol was 59 
mm, which is significantly higher than 24 mm of lipid emulsion 
propofol, and incidence of injection pain over VAS 30 mm was 
69.7% for microemulsion propofol and 42.3% for lipid emulsion 
propofol. It is known that aqueous free propofol causes pain, 
depending on concentration [14]. As for aqueous free propofol 
concentration, microemulsion propofol (Aquafol
Ⓡ) is 63.3 ± 
1.2 μg/ml and lipid emulsion propofol (Diprivan
Ⓡ) is 12.4 ± 0.7 
μg/ml, which is about 5­fold higher and pain is caused more in 
microemulsion propofol [15].
    There are several methods to reduce injection pain of 
propofol, including diluting propofol with 5% glucose solution 
or 10% intralipid [1], using opioids (fentanyl, remifentanil, etc.) 
as pretreatment [11,12], injecting lidocaine through tourniquet 
before propofol injection [13], injecting cold (4
oC) saline before 
propofol injection [16], mixing propofol with lidocaine [1], and 
using the large vein [12].
    In this study, pretreatment with sufentanil, an opioid, which is 
one of the methods to prevent injection pain of microemulsion 
propofol, was carried out. Among sufentanil pretreatment 
groups, the degree of pain was significantly low, compared to 
the control group, but there was no significant difference in 
the incidence of injection pain. According to Honarmand and 
Safavi [12], in the case of injecting lipid emulsion propofol, 
pretreatment with sufentanil 0.01 mg did not reduce the 
incidence and degree of injection pain, because the injected 
dose level of sufentanil was not sufficient or injection time 
period of lipid emulsion propofol after pretreatment was 1 
minute, which was not adequate. In this study, the reason why 
the incidence of injection pain of microemulsion propofol did 
not reduce may have been the injected dose level of sufentanil 
was not sufficient (0.1 μg/kg or 0.2 μg/kg). Even after increasing 
the dose to 0.3 μg/kg, the incidence did not reduce but it was 
shown that the degree of injection pain reduced significantly. 
Since microemulsion propofol has more injection pain than 
lipid emulsion propofol, it is expected that by applying a dose 
higher than 0.3 μg/kg of sufentanil, there may be reduction of 
the incidence or degree of injection pain in the additional study.
    According to Song et al. [17], as a result of comparison 
between injection pain of lipid emulsion propofol and lower 
lipid propofol, the incidence of mild injection pain was 39% 
after injecting 1% lidocaine 0.5 mg/kg to reduce injection pain, 
sufentanil 0.1 μg/kg or fentanyl 1 μg/kg for anesthetic induction, 
and injecting lower lipid propofol. In our study, all patients in 
the sufentanil 0.1 μg/kg pretreatment group claimed over mild 
pain. This means that Song’s study carried out pretreatment 
with lidocaine, injected lower lipid propofol, and did not 
analyze sufentanil and fentanyl separately, which causes 
the difference to the results of our study. Sufentanil reduces 
injection pain of microemulsion propofol, but injection pain is 
not removed completely within the used analgesic dose (0.1-
0.3 μg/kg).
    Sufentanil is a synthetic opioid, which is phenylpiperidine­
type, and mostly acts in the central nervous system, but can 
also act as an analgesic through opioid receptors of peripheral 
sensory nerves due to the peripheral mechanism [18]. 
Sufentanil shows a rapid onset of action, reaches the maximized 
effects at about 5-7 minutes [19], prevents hypertension and 
tachycardia during surgery [20], and does not accumulate in 
tissues. Therefore, if applying the same amount, compared 
to fentanyl which is a similar type of opioid, it is possible to 
recover faster from surgery [21]. However, by applying a high 
dose of sufentanil (over 2.6 μg/kg), respiratory depression, 
increase in airway resistance, or muscle stiffness after surgery 
may occur, which is less harmful than the effects of fentanyl 88 www.ekja.org
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[20]. This is related to the dose of sufentanil, and in this study, a 
dose of up to 0.1-0.3 μg/kg was injected as the analgesic dose 
[12,21]. Other adverse effects include drowsiness, sedation, 
clouding of consciousness, postoperative nausea, vomiting, and 
constipation. The incidence of respiratory depression, which 
is the most severe adverse effect, occurred about 0.1-1% of 
the time, regardless of injection routes, but was still possible 
to prevent [21]. In this study, one patient in the sufentanil 0.3 
μg/kg pretreatment group complained of dizziness, and pulse 
oxygen saturation of one patient dropped temporarily, which 
suggests that sufentanil might show central nervous system 
complications under 0.3 μg/kg dose, which is not a high dose 
based on the patients. 
    According to Böhrer et al. [22], when injecting 7 μg/kg fentanyl 
to the central veins, 45.9% of patients claimed coughing. It 
is assumed that this triggered chemoreflex of the lung, and 
in case of injecting to peripheral veins, one patient claimed 
coughing. In this study, it was shown that one person each in 
the sufentanil 0.1 μg/kg and sufentanil 0.3 μg/kg pretreatment 
groups claimed coughing, which means coughing may also be 
caused by a small amount.
    Opioids suppress the reflex of upper respiratory tracts, 
trachea, lower respiratory system and obtund the reflex of 
somatic or autonomic nervous system in the case of endo­
tracheal intubation [21]. In this study, there were no significant 
difference in baseline, 5 minutes after pretreatment, after loss 
of eyelid reflex, and 5 minutes after endotracheal intubation in 
systolic and diastolic blood pressure for each group but right 
after endotracheal intubation, systolic and diastolic blood 
pressure reduced significantly in sufentanil pretreatment 
groups compared to the control group. Heart rate significantly 
reduced in the sufentanil 0.3 μg/kg pretreatment group right 
after endotracheal intubation. This means that stable blood 
pressure and heart rate are maintained in pretreatment of 
sufentanil 0.3 μg/kg.
    After injecting lipid emulsion propofol (Diprivan
Ⓡ), the 
incidence of phlebitis is reported as below 6.6% [23], and 
in this study, one person each was observed in the control 
and sufentanil 0.1 μg/kg pretreatment group, for whom the 
incidence of phlebitis was 2.5% 24 hours after the surgery. Both 
suffered from severe injection pain, and as a result of observing 
the vein after replacing injection area, they improved without 
aggravation. However, this phlebitis might have occurred 
without injection pain [23], so it is important to carefully 
monitor the injection area after the injection.
    According to Nathanson et al. [24], as for patients with 
premedication of benzodiazepine, 52% recalled injection 
pain of lipid emulsion propofol. In our study, 53% of patients 
also recalled injection pain, which was significantly low in the 
sufentanil 0.3 μg/kg pretreatment group (22.2%). It is thought 
that the incidence of over moderate pain was lower in the 
sufentanil 0.3 μg/kg pretreatment group compare to the other 
groups.
    In summary, with pretreatment using sufentanil, the degree of 
injection pain of microemulsion propofol decreased, and in the 
case of injecting 0.3 μg/kg of sufentanil, the degree of injection 
pain reduced, with minimal changes in blood pressure and 
heart rate on stimulation of endotracheal intubation without 
significant adverse effects. 
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